Novo Nordisk Hikes Guidance on Strong Wegovy Sales
Novo Nordisk raised its 2026 full-year guidance after strong sales performance from its newly launched Wegovy obesity pill. The company's CEO expressed optimism about expanding the weight-loss market in the U.S.